PCM
LCTX icon

Pointe Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Pointe Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-89,523
Closed -$204K – 149
2016
Q2 		$204K Hold
89,523
– – 0.15% 142
2016
Q1 		$225K Sell
89,523
-7,520
-8% -$16.8K 0.18% 126
2015
Q4 		$321K Hold
97,043
– – 0.23% 116
2015
Q3 		$235K Hold
97,043
– – 0.14% 145
2015
Q2 		$284K Hold
97,043
– – 0.13% 143
2015
Q1 		$389K Buy
+97,043
New +$336K 0.18% 102

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $305M AUM 95.53% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return